吐温80在深部脏器肿瘤热化疗中的应用研究  

The Initial Application of Tween 80 in Thermochemotherapy of Deep Seated Tumors

作　　者：彭楠[1] 赵彼得[1] 郭新娜[1] 

机构地区：[1]解放军总医院,北京100853

出　　处：《现代生物医学进展》2006年第4期40-41,50,共3页Progress in Modern Biomedicine

摘　　要：目的：研究热增敏剂吐温80在深部肿瘤热化疗中的临床应用疗效。方法：采用吐温80合并热化疗综合治疗晚期肿瘤118例，并与同时期未采用吐温80的热化疗组98例进行比较。膀胱癌复发5例，伴腹水、腹膜转移7例。小剂量化疗用5-FU、丝裂霉素、顺铂等行膀胱灌注或腹腔注射，吐温80浓度为0．2％。肿瘤射频热疗机，f：41MHz。平均随访时间36个月。结果：复发性膀胱癌完全缓解率达60％，血尿消失，3例在12～34月随访期间膀胱镜检查未复发；伴腹水者完全缓解率达85．7％（CR6／7），中位生存期8．5月，腹痛、腹胀、便血等消失。治疗未引起恶心、呕吐等明显的消化道症状，肝、肾和骨髓功能损害。结论：在肿瘤的热化疗中。合用吐温80不仅可以降低化疗药物的剂量，而且降低热疗时的温度，减少毒副作用，改善症状和体征。Objective： To observe the therrnat sensitization effect of Tween 80. Methods： 12 patients with advanced stage malignant tumors were given thermochemotherapy（TCT） combined with Tween 80. Five of them were bladder cancer and 7 had intraperitoneal metastases with malignant ascites. After irrigation of bladder and intrapefitoneal injection with solution containing small amount 5 - FU and mitomycin and cisplatin, local thermotherapy with RF heating machine （f： 41MHz）were carried out, Tween 80 was added into the solution with final concentration of 0.2%. Results： For recurred bladder cancer, complete remission rate（CRR） was 60% with disappeared hemourine and 12- 34 months of follow- up revealed no recurrence in 3 cases. For peritoneal metastases, CRR was 85.7%of patients with a median survival of 8.5 months, abdominal pain and distension and bloody stool disapeared. No obvious nausea, vomiting, liver, renal and myeloid functional lesion were observed during the treatment. Conclusions： In TCT of malignant tumors, combination of Tween 80 can not only reduce the dosage of chemical drugs but also lower the therapeutic temperature and toxicity.

关 键 词：吐温80 热疗 肿瘤 

分 类 号：R730.53[医药卫生—肿瘤] TQ460.6[医药卫生—临床医学]